Last year, as the public made Pfizer, Johnson & Johnson, and Moderna household names, pharmaceutical companies took their cue. They poured more cash into unbranded campaigns compared to past years. Also under discussion this week is an intriguing executive move at Novartis. CEO Vas Narasimhan created a new position to oversee the company’s corporate strategy—then hired a high-profile Wall Street analyst to take the lead. And a journalist from Fierce Life Sciences heads to the Azbee Awards.

To learn more about the topics in this episode:

The top advertisers in Big Pharma

Novartis hires seasoned Wall Street analyst Ronny Gal as new M&A czar

Pfizer signals big M&A plans with new CFO Denton, the money manager behind the CVS-Aetna merger

Pfizer's blood pressure med recall creeps into US as testing flags carcinogen threat

Ardelyx's Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanor

Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna

Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends

Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe

SURMOUNT-able: Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity

The Top Line is produced by senior multimedia producer Teresa Carey, with editor-in-chief Tracy Staton, managing editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.

 

Last year, as the public made Pfizer, Johnson &amp; Johnson, and Moderna household names, pharmaceutical companies took their cue. They poured more cash into unbranded campaigns compared to past years. Also under discussion this week is an intriguing executive move at Novartis. CEO Vas Narasimhan created a new position to oversee the company&rsquo;s corporate strategy&mdash;then hired a high-profile Wall Street analyst to take the lead. And a journalist from Fierce Life Sciences heads to the Azbee Awards.
To learn more about the topics in this episode:
<a href="https://https//www.fiercepharma.com/special-reports/top-advertisers-in-big-pharma" aria-label="Link The top advertisers in Big Pharma">The top advertisers in Big Pharma</a>
<a href="https://https//www.fiercepharma.com/pharma/novartis-hires-seasoned-wall-street-analyst-ronny-gal-new-ma-czar" aria-label="Link Novartis hires seasoned Wall Street analyst Ronny Gal as new M&amp;A czar">Novartis hires seasoned Wall Street analyst Ronny Gal as new M&amp;A czar</a>
<a href="https://https//www.fiercepharma.com/pharma/pfizer-signals-big-ma-new-cfo-denton-money-manager-behind-cvs-aetna-megamerger" aria-label="Link Pfizer signals big M&amp;A plans with new CFO Denton, the money manager behind the CVS-Aetna merger">Pfizer signals big M&amp;A plans with new CFO Denton, the money manager behind the CVS-Aetna merger</a>
<a href="https://https//www.fiercepharma.com/pharma/pfizers-blood-pressure-med-recall-creeps-us-testing-again-flags-potential-cancer-agents#:~:text=After%20high%20levels%20of%20potential,quinapril%E2%80%94above%20acceptable%20daily%20limits." aria-label="Link Pfizer's blood pressure med recall creeps into US as testing flags carcinogen threat">Pfizer's blood pressure med recall creeps into US as testing flags carcinogen threat</a> <a href="https://https//www.fiercepharma.com/pharma/ardelyxs-hail-mary-caught-fda-agrees-appeal-convene-advisory-committee-tenapanor" aria-label="Link Ardelyx's Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanor">Ardelyx's Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanor</a>
<a href="https://https//www.fiercepharma.com/marketing/mercks-c-suite-shakeup-logs-another-loss-human-health-marketing-lead-jumps-ship-moderna" aria-label="Link Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna">Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna</a>
<a href="https://https//www.fiercebiotech.com/biotech/nektar-guts-workforce-weeks-after-36b-bristol-myers-immuno-oncology-collaboration-ends" aria-label="Link Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends">Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends</a>
<a href="https://https//www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe" aria-label="Link Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe">Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe</a>
<a href="https://https//www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe"></a><a href="https://https//www.fiercebiotech.com/biotech/surmount-able-lillys-tirzepatide-clears-high-bar-set-novos-wegovy-obesity" aria-label="Link SURMOUNT-able: Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity">SURMOUNT-able: Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity</a>
<a href="https://https//www.fiercebiotech.com/biotech/surmount-able-lillys-tirzepatide-clears-high-bar-set-novos-wegovy-obesity"></a>The Top Line is produced by senior multimedia producer Teresa Carey, with editor-in-chief Tracy Staton, managing editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our &ldquo;Fierce&rdquo; journalists.<a href="https://https//www.fiercebiotech.com/biotech/surmount-able-lillys-tirzepatide-clears-high-bar-set-novos-wegovy-obesity"></a><a href="https://https//www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe"></a>
&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement